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Conclusions. Female gender, hyperphosphatemia, high al-Risk factors and mortality associated with calciphylaxis in end-
kaline phosphatase, and low serum albumin are risk factorsstage renal disease.
for calciphylaxis. Calciphylaxis is associated with a very highBackground. We conducted a case control study to determine
mortality.risk factors and mortality associated with calciphylaxis in end-
stage renal disease.
Methods. Cases of calciphylaxis diagnosed between Decem-
ber 1989 and January 2000 were identified. Three controls Calciphylaxis is a condition that has been recognizedwere identified for each hemodialysis patient, with calciphylaxis
and reported in the end-stage renal disease (ESRD) pop-matched to the date of initiation of hemodialysis. Laboratory
ulation with increasing frequency in the last decade [1–5].data and medication doses were recorded during the 12 months
prior to the date of diagnosis and at the time of diagnosis It is characterized by painful and pruritic skin lesions,
of calciphylaxis. Conditional logistic regression was used to subcutaneous nodules, skin necrosis, ulceration, and es-
identify risk factors for calciphylaxis. Cox proportional hazards char formation. Medial calcification and intimal prolifer-
models were used to estimate the risk of death associated with
ation of small arteries are observed in skin biopsies ofcalciphylaxis.
patients with calciphylaxis [3, 4, 6]. In the early 1960s,Results. Nineteen cases and 54 controls were identified. Eigh-
teen patients were hemodialysis patients, and one had a func- Selye, Gabbiani, and Strebel described an animal model
tioning renal allograft. Diagnosis was confirmed by skin biopsy of calciphylaxis in which sensitization by a systemic
in 16 cases. Women were at a sixfold higher risk of developing calcifying factor such as vitamin D compounds or para-
calciphylaxis (OR  6.04, 95% CI 1.62 to 22.6, P  0.007).
thyroid hormone, followed by topical treatment withThere was a 21% lower risk of calciphylaxis associated with
certain challengers, caused an acute local calcinosis fol-each 0.1 g/dL increase in the mean serum albumin during the
year prior to diagnosis and at the time of diagnosis of calciphy- lowed by inflammation and sclerosis [7]. Selye, Gabbiani,
laxis (OR  0.79, 95% CI, 0.64 to 0.99, P  0.037, and OR  and Strebel’s studies suggested that the uremia in ne-
0.80, 95% CI, 0.67 to 0.96, P  0.019, respectively). There was phrectomized rats with intact parathyroid glands may
a 3.51-fold increase in the risk of calciphylaxis associated with
sensitize and thus promote the development of calciphy-each mg/dL increase in the mean serum phosphate during the
laxis. However, the absence of vascular calcification inyear prior to diagnosis (95% CI, 0.99 to 12.5, P 0.052). At the
time of diagnosis of calciphylaxis, for each 10 IU/L increment in Selye, Gabbiani, and Strebel’s model of experimental
alkaline phosphatase, the risk of calciphylaxis increased by calciphylaxis has led some authors to suggest alternative
19% (OR  1.19, 95% CI, 1.00 to 1.40, P  0.045). Body mass terms such as “calcific uremic arteriolopathy” for human
index, diabetes, blood pressure, aluminum, and higher dosage
lesions. Calciphylaxis is associated with high morbidityof erythropoietin and iron dextran were not independent pre-
and mortality resulting primarily from local and systemicdictors of calciphylaxis. Calciphylaxis independently increased
the risk of death by eightfold (OR  8.58, 95% CI, 3.26 to infections. The pathogenesis and risk factors for calci-
22.6, P  0.001). phylaxis remain poorly understood. Reports have sug-
gested an association between calciphylaxis and elevated
parathyroid hormone levels, elevated serum phosphateKey words: hyperphosphatemia, alkaline phosphatase and calciphy-
levels, and elevated calcium-phosphate products in manylaxis, serum albumin and calciphylaxix, death and calciphylaxis, skin
lesions and mortality. but not all patients with this condition [3, 6]. Parathyroid-
ectomy is the only therapeutic modality known to im-Received for publication October 26, 2000
prove outcome in some patients with calciphylaxis [1, 6].and in revised form February 7, 2001
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have been uncontrolled, and there have been no studies all cases. The lesions were categorized as proximal (ex-
tremities proximal to knees and elbows, trunk, breast,estimating the relative risk of mortality associated with
calciphylaxis. We conducted a case control study to iden- and penile) and distal (extremities distal to knees and
elbows). The management of pain and lesions (conserva-tify risk factors and to estimate the risk of death associ-
ated with calciphylaxis. tive vs. parathyroidectomy) was also recorded.
The following data were abstracted at the time of
diagnosis of calciphylaxis and as mean values over the
METHODS
12 months preceding the date of diagnosis: predialysis
Study population systolic and diastolic blood pressures, serum calcium,
serum phosphate, calcium-phosphate product, intact para-Cases. Nineteen patients diagnosed with calciphylaxis
between December 1989 and January 2000 at the Univer- thyroid hormone (iPTH) level, serum albumin, serum
alkaline phosphatase, and serum aluminum levels. Thesity of Washington Medical Center, Harborview Medical
Center, and Swedish Hospital in Seattle (WA, USA) medications recorded at the time of diagnosis of calciphy-
laxis included intravenous iron, oral and intravenous vi-were identified. Sixteen patients underwent skin biopsies
and had histologic evidence of calciphylaxis. All but one tamin D preparations, erythropoietin, and warfarin. The
cumulative dosage of intravenous iron, intravenous vita-patient had been on chronic hemodialysis prior to the
diagnosis of calciphylaxis. The remaining patient had a min D preparations, and erythropoietin for 12 months
preceding the date of diagnosis of calciphylaxis was alsofunctioning cadaveric renal allograft. All patients were
treated with conservative management, including pain recorded. The data listed here were abstracted for each
control using the date of diagnosis of calciphylaxis forcontrol, wound debridement and dressings, antibiotics,
discontinuation of calcium salts and vitamin D prepara- the corresponding case.
tions, phosphate restriction, and a lower calcium concen-
Outcome measurestration in the dialysate. Six patients underwent parathy-
roidectomy. The diagnosis of calciphylaxis was based on the pres-
ence of painful and pruritic skin lesions and subcutane-Controls. The controls were identified from the pa-
tients receiving hemodialysis at the Northwest Kidney ous nodules complicated by ulceration and eschar forma-
tion in advanced stages of the condition. The diagnosisCenter (NWKC) in Seattle (WA, USA). Three controls
(N  54) were identified for each case (N  18) and was confirmed by the presence of medial calcification
and intimal hyperplasia of small arteries (subcutaneousmatched for the date of initiation of hemodialysis (2
months). The controls were required to be alive on the and digital) and cutaneous and fat necrosis on skin biopsy
in 16 patients (84%). The occurrence and cause of deathdates corresponding to the dates of diagnosis of calciphy-
laxis for the corresponding case. A control was not identi- were determined from the Health Care Financing Ad-
ministration ESRD Death Notification Form (HCFA-fied for the transplant patient.
2746).
Data collection
Statistical analysisA retrospective review of the hospital and dialysis rec-
ords of all cases and controls was performed. The follow- Body mass index (BMI) at the time of diagnosis of
calciphylaxis in cases and at the corresponding dates foring demographic data were abstracted: age, gender, and
race (African American, Caucasian, other). Medical data controls was calculated from height and weight (kg/m2).
Calcium was corrected for serum albumin (serum cal-abstracted included primary cause of ESRD (diabetes
mellitus, hypertension, glomerulonephritis, other), date cium 0.6 mg/dL for each 1 g/L of serum albumin above
or below 4 g/dL). The calcium-phosphate product wasof first ESRD treatment, treatment modality (hemodial-
ysis, peritoneal dialysis, renal transplant), and history of calculated using serum calcium levels corrected for se-
rum albumin. The duration of chronic renal replacementdiabetes. The height and weight at the time of diagnosis
of calciphylaxis (and at the corresponding time for con- therapy was calculated as the difference between the
date of the first treatment for ESRD and the date oftrols) were recorded.
Among patients with parathyromatosis, a history of diagnosis of calciphylaxis for each case. The duration of
ESRD treatment for each control was calculated as thehypercoagulable states (deficiencies of protein C, protein
S, and antithrombin III, lupus inhibitor, antiphospholipid difference between the date of first treatment for ESRD
and the date of diagnosis of calciphylaxis for the corre-syndromes, and factor II and factor V mutations) was
ascertained from the medical records when available. sponding case.
Laboratory and medication data were available at theThe clinical features (pain, pruritus, rash, ulceration, es-
char formation, infected lesions) and histologic features time of diagnosis and for the 12 months prior to the diag-
nosis of calciphylaxis. To summarize data generated over(calcification of small arteries, intimal hyperplasia, skin
necrosis, fat necrosis) of calciphylaxis were recorded for the 12 months prior to diagnosis, laboratory values were
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averaged, while medication doses were summed. For No penile lesions were identified. Six of seven patients
evaluated (86%) had fine double lines on their x-rays,descriptive purposes, patients were grouped by disease
status, and patient characteristics were grouped as being suggesting calcified small blood vessels. Of seven patients
evaluated for hypercoagulable states, one had protein Smeasured prior to and at the time of diagnosis of calci-
phylaxis. The continuous data are summarized as mean deficiency (14%), and one had antiphospholipid antibod-
ies (14%). Six patients were treated with a parathyroid-and standard deviation. A comparison of baseline char-
acteristics across disease groups was performed using ectomy. Indications included severe pain despite analge-
sics (N  6), nonhealing lesions (N  4), and elevatedchi-square tests for discrete variables, two-sample t tests
for normally distributed continuous variables, and non- iPTH levels (N  5).
The characteristics of cases and controls over the 12parametric permutation tests for highly skewed continu-
ous variables. months prior to the diagnosis and at the time of diagnosis
of calciphylaxis are shown in Tables 1 and 2. The twoMultivariate analysis was performed on the 18 hemo-
dialysis patients and 54 controls. The predictors of devel- groups were similar with regard to age at the time of
diagnosis of calciphylaxis, history of diabetes mellitus,oping calciphylaxis were determined using conditional
logistic regression due to the matched case-control study and BMI at the time of diagnosis. The cases were more
likely to be female and of Caucasian origin. The adjusteddesign. The univariate regression model estimates, in-
cluding odds ratios, 95% confidence intervals, and P val- serum calcium levels were not significantly different be-
tween the two groups when compared at the time ofues to test association, are presented for all available
predictors. The P values presented for univariate results diagnosis or as mean values over 12 months prior to the
diagnosis. The cases had lower serum albumin levels,were not adjusted for multiple comparisons. Two sepa-
rate multivariate regression models are presented, one higher serum phosphate levels, and higher alkaline phos-
phatase levels compared with controls at the time offor predictors of calciphylaxis measured over the 12
months prior to diagnosis and the other for predictors diagnosis and over the 12 months preceding the diagnosis
of calciphylaxis. Although not statistically significant,at the time of diagnosis of calciphylaxis. The objective
there was a trend toward higher adjusted calcium-phos-in doing so was to allow a comparison of the similarities
phate products and higher iPTH levels in the cases asand differences between the long-term risk factors for
compared with controls. The dosage of erythropoietincalciphylaxis to the risk factors present at the time of
at the time of diagnosis of calciphylaxis was higher in thediagnosis. The covariates included in the multivariate
cases than the controls. The predialysis diastolic bloodmodels were chosen based on (1) the biological plausibil-
pressures at the time of diagnosis and over the precedingity of an association with the occurrence of calciphylaxis,
12 months were similar for the two groups.(2) the possibility that they may confound the relation-
Table 3 shows the unadjusted risk of developing calci-ship between the occurrence of calciphylaxis and another
phylaxis associated with risk factors during the 12 monthspredictor of interest, and/or (3) the magnitude of their
prior to the diagnosis of calciphylaxis. Each incrementunivariate relationship with the presence of calciphy-
in serum albumin by 0.1 g/dL was associated with anlaxis.
approximately 25% lower likelihood of developing calci-The Cox proportional hazards model was used to ana-
phylaxis (OR  0.76, 95% CI, 0.64 to 0.94). A 2.7-foldlyze the time from the diagnosis of calciphylaxis (or the
higher risk of developing calciphylaxis was observed withcorresponding time for controls) to death from any
each increment in serum phosphate level by 1 mg/dLcause, with data censored on June 1, 2000, or if a patient
(OR  2.73, 95% CI, 1.28 to 5.78). An increased likeli-became lost to follow-up prior to the end of study. The
hood of developing calciphylaxis was associated withpresence or absence of calciphylaxis, diabetic status, and
higher serum alkaline phosphatase levels (OR  1.36,the time spent on dialysis prior to the date of diagnosis of
95% CI, 1.01 to 1.83, respectively). There was a trendcalciphylaxis were examined as risk factors for mortality.
toward a higher risk of developing calciphylaxis withThe univariate and multivariate survival model esti-
higher serum levels of iPTH over 12 months prior tomates, including relative risks, 95% confidence intervals,
diagnosis.and P values to test association, are presented for the
Table 3 also shows the unadjusted risk of developingpreviously mentioned risk factors. Survival curves com-
calciphylaxis associated with risk factors at the time ofparing patients with and without calciphylaxis are also
diagnosis of calciphylaxis. The likelihood of developingpresented.
calciphylaxis was sixfold higher in females compared
with males (OR  6.04, 95% CI, 1.62 to 22.6). Although
RESULTS not statistically significant, older patients showed a trend
Nineteen cases of calciphylaxis were identified. Four- toward a lower relative risk of developing calciphylaxis.
teen patients had proximal lesions. Nine had distal le- Each increment in serum albumin by 0.1 g/dL was associ-
ated with a 27% lower likelihood of developing calciphy-sions, and four had both proximal and distal lesions.
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Table 1. Patient characteristics prior to diagnosis
Controls (N  54) Cases (N  19)
Available
Characteristic cases Mean (SD) or % (N)
Demographic data
Age years 73 61.0 (15.5) 53.6 (11.6)
Female gender 73 39% (21) 79% (15)a
Race 73
White 37% (20) 63% (12)a
Black 31% (17) 26% (5)
Other 31% (17) 11% (2)
Co-morbid conditions
Presence of diabetes 73 39% (21) 42% (8)
Primary cause of ESRD 73
Diabetes 37% (20) 42% (8)
Hypertension 13% (7) 5% (1)
Glomerulonephritis 22% (12) 11% (2)
Other 28% (15) 37% (7)
Duration of ESRD years 73 3.3 (2.8) 4.2 (4.6)
12-month average BP and laboratory measurements
Pre-diastolic BP mm Hg 65 82.1 (10.8) 79.9 (11.7)
Post-diastolic BP mm Hg 65 77.9 (10.4) 74.2 (8.4)
Albumin g/dL 65 3.35 (.36) 2.88 (.49)a
Phosphate mg/dL 65 5.1 (1.3) 6.8 (1.7)a
Calcium mg/dL 65 9.13 (.71) 8.86 (1.32)
Calcium-phosphate product 65 46.5 (11.3) 60.8 (17.3)
iPTH pg/mL 60 312.5 (481.0) 359.2 (435.4)
Alkaline phosphatase IU/L 65 85.7 (40.8) 165.5 (180.4)a
Aluminum mg/dL 51 10.3 (18.1) 24.2 (26.3)
12-month cumulative medication doses
Calcitriol lg 72 37.7 (59.6) 27.6 (53.8)
Erythropoietin per 1000 units 69 337.3 (336.1) 473.3 (411.1)
Iron dextran mg 71 2028.0 (4312.7) 1125.0 (1411.3)
Medications at diagnosis
Warfarin 1 (1.8%) 7 (37%)
Prednisone 3 3
Calcitriol 3 4
Calcium salts 40 (69%) 14 (78%)
Abbreviations are: BP, blood pressure; ESRD, end-stage renal disease.
a Groups were significantly different, P  0.01
Table 2. Patient characteristics at the time of diagnosis
Controls (N  54) Cases (N  19)
Available
Characteristic cases Mean (SD) or % (N)
BP and laboratory measurements
Pre-diastolic BP mm Hg 65 79.0 (13.2) 73.3 (18.0)
Post-diastolic BP mm Hg 65 75.0 (13.3) 71.5 (14.2)
BMI kg/m2 67 24.6 (5.22) 25.9 (6.41)
Albumin g/dL 65 3.38 (.35) 2.62 (.73)a
Phosphate mg/dL 65 4.9 (1.7) 6.2 (1.8)a
Calcium mg/dL 65 9.15 (.74) 9.06 (1.09)
Calcium-phosphate product 65 44.1 (14.7) 56.1 (16.2)
iPTH pg/mL 60 283.0 (459.0) 420.0 (441.0)
Alkaline phosphatase IU/L 65 86.4 (47.8) 170.0 (132.3)a
Aluminum mg/dL 51 7.7 (8.0) 19.3 (23.5)a
Medication doses
Calcitriol lg 72 0.68 (0.91) 0.61 (0.64)
Erythropoietin units 69 3979.4 (3792.2) 7539.0 (4498.6)a
Iron dextran mg 71 108.1 (145.4) 90.8 (151.7)
a Groups were significantly different, P  0.01
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Table 3. Univariate conditional logistic model results for predictors measured over the 12 months prior to and at the time of
diagnosis of calciphylaxis
Odds of calciphylaxis
Measurements prior to diagnosisa Measurements at the time of diagnosis
Covariate OR (95% CI) P value OR (95% CI) P value
Demographic data
Age (1 year increase) 0.96 (0.92, 1.00) 0.070 0.96 (0.92, 1.00) 0.070
Female gender 6.04 (1.62, 22.6) 0.007 6.04 (1.62, 22.6) 0.007
Race 0.139 0.139
White 1.0 1.0
Black 0.94 (0.15, 1.65) 0.250 0.94 (0.15, 1.65) 0.250
Other 0.18 (0.03, 1.03) 0.054 0.18 (0.03, 1.03) 0.054
Co-morbid conditions
Diabetes (yes vs. no) 1.31 (0.40, 4.32) 0.655 1.31 (0.40, 4.32) 0.655
Primary cause of ESRD 0.424 0.424
Diabetes 1.0 1.0
Hypertension 0.40 (0.04, 3.87) 0.430 0.40 (0.04, 3.87) 0.430
Glomerulonephritis 0.20 (0.02, 2.05) 0.175 0.20 (0.02, 2.05) 0.175
Polycystic kidney disease 0.60 (0.06, 6.12) 0.669 0.60 (0.06, 6.12) 0.669
Other 1.36 (0.35, 5.26) 0.659 1.36 (0.35, 5.26) 0.659
BP and laboratory measurements
Pre-diastolic BP per mm Hg 0.98 (0.93, 1.04) 0.518 0.96 (0.92, 1.01) 0.154
Post-diastolic BP per mm Hg 0.97 (0.90, 1.03) 0.323 0.98 (0.93, 1.03) 0.441
BMI per kg/m2 Not available 1.03 (0.93, 1.14) 0.518
Albumin per 0.1 g/dL 0.76 (0.64, 0.94) 0.011 0.73 (0.60, 0.89) 0.002
Phosphate per mg/dL 2.73 (1.28, 5.78) 0.009 1.85 (1.17, 2.93) 0.008
Calcium per mg/dL 0.49 (0.21, 1.15) 0.102 0.91 (0.50, 1.65) 0.748
Calcium-phosphate product 1.08 (1.01, 1.16) 0.017 1.06 (1.02, 1.11) 0.008
iPTH per 50 pg/mL 1.23 (0.97, 1.57) 0.088 1.02 (0.97, 1.09) 0.424
Alkaline phosphatase per 10 IU/L 1.36 (1.01, 1.83) 0.041 1.12 (1.02, 1.22) 0.012
Aluminum per mg/dL 1.02 (0.98, 1.07) 0.265 1.10 (0.98, 1.25) 0.115
Medication doses
Calcitriol per lg 1.00 (0.99, 1.01) 0.625 0.94 (0.49, 1.80) 0.854
Erythropoeitin per 500 units 1.00 (0.99, 1.00) 0.125 1.13 (1.04, 1.23) 0.005
Iron dextran per 50 mg 0.97 (0.93, 1.01) 0.129 0.93 (0.69, 1.25) 0.619
a Laboratory measurements are averaged over the 12 months prior to diagnosis; medication doses are cumulative over the 12 months prior to diagnosis
laxis (OR 0.73, 95% CI, 0.60 to 0.89). A 2.7-fold higher 20% (OR  0.79, 95% CI, 0.64 to 0.99, and OR  0.80,
95% CI, 0.67 to 0.96). The risk of developing calciphy-risk of developing calciphylaxis was observed with each
increment in serum phosphate level by 1 mg/dL at the laxis was increased 3.5-fold for each 1 mg/dL increase
in serum phosphate level over 12 months prior to diagno-time of diagnosis of calciphylaxis (OR  1.85, 95% CI,
1.17 to 2.93). An increased likelihood of developing calci- sis of calciphylaxis (OR  3.51, 95% CI, 0.99 to 12.5).
For each 10 IU/L increment in alkaline phosphatase atphylaxis was associated with higher serum alkaline phos-
phatase levels (OR  1.12, 95% CI, 1.02 to 1.22). A the time of diagnosis of calciphylaxis, there was a 19%
increased risk of calciphylaxis (OR 1.19, 95% CI, 1.0013% increase in the risk of developing calciphylaxis was
estimated for each 500 unit increment in erythropoietin to 1.40).
Eleven patients with calciphylaxis and seven controlsdose at the time of diagnosis (OR  1.13, 95% CI, 1.04
to 1.23). Higher dosages of calcitriol and iron dextran died during the follow-up period. Seven out of 10 patients
who died of complications related to calciphylaxis hadwere not associated with the risk of developing calciphy-
laxis. proximal lesions. Infection of lesions was the major cause
of death in six patients, and four of these patients hadTable 4 illustrates the adjusted relative risk of devel-
oping calciphylaxis associated with potential risk factors proximal lesions. One patient with calciphylaxis had bi-
lateral breast lesions, and none of the cases had penileat the time of diagnosis and for 12 months prior to the
diagnosis of calciphylaxis in our final model. Female gen- involvement. Calciphylaxis was complicated by infection
of the lesions in 12 patients (63%).der was independently associated with a fivefold to seven-
fold higher risk of developing calciphylaxis (OR  6.87, Figure 1 illustrates the survival curves for cases and
controls. The cases had an estimated one-year survival95% CI, 0.50 to 94.7, and OR  5.53, 95% CI, 0.53 to
57.3). Each increment in serum albumin level by 0.1 g/dL rate of 45% compared with 90% for the controls. The
five-year survival was 35% for the cases and 60% forprior to diagnosis and at the time of diagnosis of calciphy-
laxis decreased the risk of developing calciphylaxis by the controls. Table 5 shows the relative risk of death
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Table 4. Multivariate conditional logistic model results for predictors measured over the 12 months prior to and at the
time of diagnosis of calciphylaxis
Odds of calciphylaxis
Measurements prior to diagnosisa Measurements at the time of diagnosis
Covariate OR (95% CI) P value OR (95% CI) P value
Female gender 5.53 (0.53, 57.3) 0.151 6.87 (0.50, 94.7) 0.150
Albumin per 0.1 g/dL 0.79 (0.64, 0.99) 0.037 0.80 (0.67, 0.96) 0.019
Phosphate per mg/dL 3.51 (0.99, 12.5) 0.052 Not included
Alkaline phosphatase per 10 IU/L Not included 1.19 (1.00, 1.40) 0.045
a Laboratory measurements are averaged over the 12 months prior to diagnosis
Fig. 1. Survivor curves comparing patients
with calciphylaxis present (dotted line) to those
without (solid line). Curve estimates were ad-
justed for the presence of diabetes and the
duration of ESRD prior to diagnosis.
associated with calciphylaxis. The presence of calciphy- of erythropoietin were also associated with an increased
laxis, diabetes mellitus, and longer duration of ESRD risk of calciphylaxis.
(hemodialysis) was independently associated with a higher Patients with calciphylaxis were at an eightfold in-
risk of death. It was estimated that the presence of calci- creased risk of death compared with controls. The differ-
phylaxis increased the likelihood of death by eightfold ence between survival curves of cases and controls in
compared with controls (RR  8.58, 95% CI, 3.26 to our study was most striking in the first year and more
22.6). The likelihood of death was estimated to increase specifically in the first few months after the diagnosis of
by fourfold in the presence of diabetes mellitus (RR  calciphylaxis. This observation is consistent with the
3.97, 95% CI, 1.25 to 11.5) and by 21% for each year of rapid disease progression associated with calciphylaxis.
ESRD therapy (RR  1.21, 95% CI, 1.02 to 1.45). Consistent with previous studies, the major cause of
death among patients with calciphylaxis was infection
[5]. The majority of cases who died had proximal lesions.DISCUSSION
Proximal lesions have been observed to be associatedThis case control study identified risk factors for calci-
with worse outcomes in previous studies [1, 5]. The in-phylaxis, and to our knowledge we are the first to esti-
creased risk of death among patients with calciphylaxismate the risk of death associated with the development
may be due to factors predisposing patients to calciphy-of calciphylaxis. In the multivariate model, risk factors
laxis such as malnutrition or complications associatedfor developing calciphylaxis included female gender, low
with the development of calciphylaxis, including infec-serum albumin, elevated serum phosphate, and higher
tion and sepsis.serum alkaline phosphatase levels. In the univariate anal-
ysis, higher calcium phosphate products and higher doses Consistent with previous reports, we have demon-
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Table 5. Cox regression results modeling time from diagnosis to all-cause mortality
Unadjusted Adjusteda
Deaths Mortality rate
Covariate (N  19) per 100 years RR (95% C.I.) P value RR (95% C.I.) P value
Presence of calciphylaxis
No 8 7.0 1.0 1.0
Yes 11 57.5 7.29 (2.88, 18.5) 0.001 8.58 (3.26, 22.6) 0.001
Presence of diabetes
No 10 10.0 1.0 1.0
Yes 9 30.0 2.13 (0.81, 5.61) 0.127 3.97 (1.25, 11.5) 0.018
Duration of ESRD years 1.13 (0.96, 1.37) 0.152 1.21 (1.02, 1.45) 0.032
a Adjusted for presence of calciphylaxis, diabetes, and duration of ESRD
strated a higher risk of calciphylaxis among females [1, 4]. calcium-phosphate metabolism has been variable in pre-
vious studies. We have demonstrated an increased riskThe relatively larger proportion of adipose tissue in fe-
males compared with males may predispose to relative of calciphylaxis among patients with elevated phosphate
prior to diagnosis and elevated alkaline phosphate at thehypoperfusion of the skin and subcutaneous tissue. Al-
ternatively, a relative increase in the subcutaneous tissue time of diagnosis. In addition, we found a trend toward
higher adjusted calcium-phosphate products and lowermay increase tensile stress on the septa connecting the
skin to the deep fascia and on arterioles resulting in serum calcium levels among patients with calciphylaxis.
We demonstrated a threefold increase in the likelihoodcutaneous hypoperfusion, and ischemic necrosis [8]. The
predominant occurrence of lesions of calciphylaxis in of developing calciphylaxis for each increment in serum
phosphate by 1 mg/dL over the 12 months prior to thelocations where adipose tissue is more abundant in the
current and previous studies, and previously reported diagnosis of calciphylaxis and a 19% increased risk of
developing calciphylaxis associated with each 10 IU/Lassociations between obesity and calciphylaxis support
this hypothesis [4, 9]. However, the majority of cases increase in alkaline phosphatase at the time of diagnosis
and a trend toward higher iPTH levels in the cases. Thisand controls in the current study were not obese (median
BMI 24 to 25), suggesting that obesity is not a prerequi- confirms previous reports of higher serum phosphate
and higher serum levels of alkaline phosphatase [3, 4,site for the development of calciphylaxis.
Our study demonstrated a higher risk of calciphylaxis 6]. Angelis et al reported median phosphate levels of 8.2
and 5.7 for calciphylaxis cases and controls, respectivelyamong Caucasian patients. This is consistent with several
studies that have reported a preponderance of Cauca- (P 0.001) [3]. The higher levels of alkaline phosphatase
may be indicative of more advanced bone disease, partic-sians among patients with calciphylaxis [1, 3–5]. All pa-
tients with calciphylaxis were Caucasian in the study ularly in the setting of relatively severe hyperparathy-
roidism in several patients with ESRD who develop calci-reported by Bleyer et al, despite an overall prevalence
of 50% African Americans in their hemodialysis popula- phylaxis. The relatively lower levels of serum calcium in
the cases may result from precipitation of calcium withtion [4]. Some investigators have suggested relative diffi-
culty in diagnosing skin lesions of calciphylaxis in pa- phosphate in blood vessels and other sites in the setting
of elevated phosphate levels and elevated calcium-phos-tients with darker skin as one possible explanation for
this observation, although other factors likely confer pro- phate products. There was a trend toward an increased
risk of developing calciphylaxis with higher levels oftection to non-Caucasian populations from developing
calciphylaxis [4]. parathyroid hormone in our study. The association of
calciphylaxis with elevated parathyroid hormone levelsThe increased risk of developing calciphylaxis associ-
ated with lower levels of serum albumin relative to con- and elevated calcium-phosphate products has been in-
consistent in previous reports. These differences may betrols has been reported previously [4]. Bleyer et al
reported a 17-fold increase in the risk of developing calci- a reflection of the small sample size and limited statistical
power to identify associations and of the multifactoralphylaxis with each decrease in albumin by l g/L (OR 
16.9, 95% CI, 5.25 to 54.5). This finding is supported by etiology of the condition [1–6]. Similarly, some reports
have suggested a benefit of parathyroidectomy. OtherCoates et al, who reported a loss of 10% body weight
over six months preceding the diagnosis of calciphylaxis studies have not shown a benefit from parathyroidec-
tomy, suggesting a multifactorial etiology of this condi-in 7 out of 16 patients in their series [2]. Low albumin
is associated with poor wound healing and an increased tion [12–14]. Our sample size was too limited to make
any conclusions about the utility of parathyroidectomy,risk of infection [10, 11], suggesting that low albumin
may predispose patients to calciphylaxis. and there are no prospective studies to confirm or refute
previous reports.The association of calciphylaxis with parameters of
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Consistent with previous reports, we discovered a tions, a strict control of serum phosphate with dietary
trend toward a higher risk of calciphylaxis in younger phosphate restriction and phosphate-binding agents in
hemodialysis patients. A longer exposure to renal re- high-risk patients appears to be important [17, 18]. Main-
placement therapy in younger patients with ESRD may taining adequate nutrition may also be important in pre-
increase the likelihood of developing calciphylaxis by venting the development of calciphylaxis. Early and ag-
increasing the exposure time to factors that predispose gressive treatment of infections complicating lesions of
to calciphylaxis [3, 15]. In contrast to some reports [4], calciphylaxis, a lower calcium concentration in the dialy-
diabetes was not a risk factor for calciphylaxis. A possible sate [19, 20], and avoidance of high calcium-phosphate
explanation for this difference is the smaller proportion products in patients with impaired renal function may
of obese diabetic patients in our study. reduce morbidity and mortality associated with calciphy-
Studies have reported associations between iron dex- laxis. Prospective controlled multicenter trials would
tran, vitamin D preparations, and calcium-containing
greatly aid in a better understanding of risk factors for
phosphate binding agents and calciphylaxis (abstract,
calciphylaxis and in the prevention and management ofBraden et al, J Am Soc Nephrol 8:549, 1997) [16]. In the
this condition.univariate analysis, we found that patients with calciphy-
laxis had been receiving higher doses of erythropoietin
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